About Terumo
About Terumo
About Terumo Top

Dear Stakeholders

Terumo Group Identity

Terumo Group Code of Conduct

Corporate Profile

Corporate Governance

Compliance

Regulations and Standards

Directors and Executive Officers

History

Procurement Activity
Back
Business Overview
Business Overview
Business Overview Top

TIS Division（Terumo Interventional Systems）

Neurovascular Division (MicroVention)

Cardiovascular Division (Terumo Cardiovascular) / HeartSheet Division

Cardiovascular Division (Terumo Cardiovascular)

HeartSheet Division

Vascular Graft Division (Terumo Aortic)

Hospital Systems Division

Alliance Division

Blood and Cell Technologies Company (Terumo Blood and Cell Technologies)
Back
Technology
Technology
Technology Top

Basic Information

Basic Information Top

Research and Development

Production and Supply

Intellectual Property

Terumo Fellows

Stories - Our Technologies
Back
Sustainability
Sustainability
Sustainability Top

News

Message from Top Management

Sustainability at the Terumo Group

Resolving Healthcare Challenges

Creating a Diverse and Inclusive Workplace

Reducing Environmental Footprint

Serving Our Communities

Report Library

Report Library Top

Back Numbers

GRI Standards Index
Back
Investors
Investors
Investors Top

Management Policy

Management Policy Top

Top Management Message

IR Policy

Business Risks

Financial Information

Financial Information Top

Quarterly Results

Financial Highlights

Segment Information

Shareholders & Stock

Shareholders & Stock Top

Stock Information

Shareholder Return

Chart

Credit Ratings and Corporate Bond

Analyst Coverage

Shareholders Meeting

Articles of Incorporation

IR Library

IR Library Top

Financial Statements

Presentations

Terumo Reports

Terumo Reports Top

Back Numbers

IR Events

Mail for IR Inquiry

Disclaimer
Back
Our Stories
Our Stories
Our Stories Top
Back
Newsroom
Newsroom
Newsroom Top

Newsroom2019

Newsroom2018

Newsroom2017

Newsroom2016

Newsroom2015

Newsroom2014
Back
Global Network
Global Network
Global Network Top

Japan

North America

South America

Europe, Middle East and Africa

Greater China

Asia and Pacific
Back

Newsroom 2015

November 5, 2015

Financial

Terumo Revises Upward Interim Dividend and Year-End Dividend Forecast for the Fiscal Year Ending March 31, 2016
September 24, 2015

Financial

Revision to First-Half and Full-Year Results Forecast for FY2015
September 18, 2015

Cardiac and Vascular

Terumo Receives Approval for the Manufacturer and Sale of its HeartSheet Autologous Skeletal Myoblast Sheets in Japan
September 9, 2015

Corporate

Terumo Invests in Quirem Medical, Focusing on Interventional Oncology Field
September 2, 2015

Corporate

Terumo's Autologous Skeletal Myoblast Sheets Are the First to Be Approved as a Cellular or Tissue-based Products in Japan by a Council of the Ministry of Health, Labour and Welfare
August 12, 2015

Financial

Notice Concerning Acquisition Results of the Company's Own Shares by ToSTNeT-3
August 11, 2015

Financial

Notice Concerning Acquisition of the Company's Own Shares through ToSTNeT-3
August 10, 2015

Cardiac and Vascular

Terumo Receives Approval for the Manufacturer and Sale of its Ultimaster Drug-Eluting Coronary Stent in Japan
August 7, 2015

Financial

Notice Concerning the Issuance of Stock Option (Share Warrants)
August 4, 2015

Financial

Notice Concerning Acquisition of the Company's Own Shares
(Acquisition of the company's own shares pursuant to item 2 of Article 165 of the Corporate Law concerning the provisions of the articles of incorporation)
June 24, 2015

Financial

Notice regarding the appointment of Independent Committee Members for the "Policy for Large-scale Acquisitions of Terumo Shares (Takeover Defense Measures"
May 28, 2015

Corporate

Terumo to Support Relief Efforts Following Nepal Earthquake
May 19, 2015

Cardiac and Vascular

Terumo Announces CE Mark Clearance for Bioresorbable Scaffold Developed by Arterial Remodeling Technologies (ART)
May 8, 2015

Corporate

Notice Concerning Members of the Board of Directors after the Transition to a Company with an Audit/Supervisory Committee
May 8, 2015

Financial

Notice Regarding Dividend for the Fiscal Year Ended March 31, 2015
April 23, 2015

Corporate

Notice Concerning Partial Amendment of the Articles of Incorporation
April 23, 2015

Corporate

Notice Concerning Transition to a Company with an Audit/Supervisory Committee
April 17, 2015

Corporate

Regarding the Result of Inspection at Terumo CVS Ann Arbor Plant
by U.S. Food & Drug Administration (FDA)
April 10, 2015

Corporate

Daiichi Sankyo and Terumo Announce Application in Japan for Manufacturing and Sales Approval of Intradermal Seasonal Influenza Vaccine
April 6, 2015

Corporate

Terumo and Olympus Expand Interventional System Business Partnership
in the U.S. to Cover Urology and Gastroenterology
March 27, 2015

Corporate

FAMHP advises patients to not suspend nor stop any treatments
March 23, 2015

Corporate

Terumo Europe responds to broadcast EenVandaag
Injection needles pose no health risks for patients
February 12, 2015

Corporate

Terumo Establishes a New R&D Center for Interventional Business in Southern California, US to Accelerate Worldwide Growth of Interventional Therapeutic Area
February 3, 2015

Financial

Notice Concerning Acquisition of the Company's Own Shares (Acquisition of the company's own shares pursuant to item 2 of Article 165 of the Corporate Law concerning the provisions of the articles of incorporation)

T
O
P